MedKoo Cat#: 464840 | Name: CD532
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CD532 is an inhibitor of Aurora A kinase activity (IC50 = 48 nM) and the protein-protein interaction between N-Myc and Aurora A kinase. It also inhibits several cyclin-dependent kinases (CDKs), FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM.2 CD532 induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50 = 223 nM). It prevents S-phase entry in SK-N-BE(2) cells when used at a concentration of 1 µM. CD532 (25 mg/kg) reduces tumor growth and increases survival in a MYCN-amplified SMS-KCN neuroblastoma mouse xenograft model.

Chemical Structure

CD532
CAS#1639009-81-6

Theoretical Analysis

MedKoo Cat#: 464840

Name: CD532

CAS#: 1639009-81-6

Chemical Formula: C26H25F3N8O

Exact Mass: 522.2103

Molecular Weight: 522.54

Elemental Analysis: C, 59.76; H, 4.82; F, 10.91; N, 21.44; O, 3.06

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
CD532; CD 532; CD-532;
IUPAC/Chemical Name
1-(4-((4-((5-cyclopentyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea
InChi Key
GBMIFBVLJSCVJT-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H25F3N8O/c27-26(28,29)17-6-3-7-20(14-17)33-25(38)32-19-10-8-18(9-11-19)31-24-30-13-12-22(35-24)34-23-15-21(36-37-23)16-4-1-2-5-16/h3,6-16H,1-2,4-5H2,(H2,32,33,38)(H3,30,31,34,35,36,37)
SMILES Code
O=C(NC1=CC=C(C=C1)NC2=NC(NC3=NNC(C4CCCC4)=C3)=CC=N2)NC5=CC=CC(C(F)(F)F)=C5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 522.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Musavizadeh Z, Grottesi A, Guarguaglini G, Paiardini A. Phosphorylation, Mg- ADP, and Inhibitors Differentially Shape the Conformational Dynamics of the A-Loop of Aurora-A. Biomolecules. 2021 Apr 12;11(4):567. doi: 10.3390/biom11040567. PMID: 33921540; PMCID: PMC8070005. 2: Gilburt JAH, Sarkar H, Sheldrake P, Blagg J, Ying L, Dodson CA. Dynamic Equilibrium of the Aurora A Kinase Activation Loop Revealed by Single-Molecule Spectroscopy. Angew Chem Int Ed Engl. 2017 Sep 11;56(38):11409-11414. doi: 10.1002/anie.201704654. Epub 2017 Aug 7. PMID: 28700101; PMCID: PMC5601181. 3: Bayliss R, Burgess SG, Leen E, Richards MW. A moving target: structure and disorder in pursuit of Myc inhibitors. Biochem Soc Trans. 2017 Jun 15;45(3):709-717. doi: 10.1042/BST20160328. PMID: 28620032. 4: Richards MW, Burgess SG, Poon E, Carstensen A, Eilers M, Chesler L, Bayliss R. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731. doi: 10.1073/pnas.1610626113. Epub 2016 Nov 11. PMID: 27837025; PMCID: PMC5137718. 5: Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L, Pantsar T, Bozko P, Malek NP, Longerich T, Laufer S, Poso A, Zucman-Rossi J, Eilers M, Zender L. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med. 2016 Jul;22(7):744-53. doi: 10.1038/nm.4107. Epub 2016 May 23. PMID: 27213815. 6: Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11;29(4):536-547. doi: 10.1016/j.ccell.2016.03.001. Epub 2016 Mar 31. PMID: 27050099; PMCID: PMC4829466. 7: Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014 Sep 8;26(3):414-427. doi: 10.1016/j.ccr.2014.07.015. Epub 2014 Aug 28. PMID: 25175806; PMCID: PMC4160413.